Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Non-Current Deffered Revenue: 2022-2024

Historic Non-Current Deffered Revenue for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Dec 2024 value amounting to $11.0 million.

  • Orchestra BioMed Holdings' Non-Current Deffered Revenue fell 24.30% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year decrease of 24.30%. This contributed to the annual value of $11.0 million for FY2024, which is 26.36% down from last year.
  • Per Orchestra BioMed Holdings' latest filing, its Non-Current Deffered Revenue stood at $11.0 million for FY2024, which was down 26.36% from $14.9 million recorded in FY2023.
  • In the past 5 years, Orchestra BioMed Holdings' Non-Current Deffered Revenue registered a high of $14.9 million during FY2023, and its lowest value of $11.0 million during FY2024.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $13.1 million (2022), whereas its average is $13.0 million.
  • Per our database at Business Quant, Orchestra BioMed Holdings' Non-Current Deffered Revenue increased by 13.89% in 2023 and then declined by 26.36% in 2024.
  • Over the past 3 years, Orchestra BioMed Holdings' Non-Current Deffered Revenue (Yearly) stood at $13.1 million in 2022, then grew by 13.89% to $14.9 million in 2023, then decreased by 26.36% to $11.0 million in 2024.